Literature DB >> 3121600

Stoichiometry of the porcine factor VIII-von Willebrand factor association.

P Lollar1, C G Parker.   

Abstract

Factor VIII and von Willebrand factor (vWF) are glycoproteins that form a tightly bound complex in plasma. The interaction of porcine factor VIII with porcine vWF was studied by analytical velocity sedimentation. A single approximately 240-kDa species of factor VIII was isolated for use in the analysis. In contrast, when analyzed by agarose/sodium dodecyl sulfate-polyacrylamide gel electrophoresis, vWF consisted of a population of greater than 10 multimers derived from a 270-kDa monomer. A single boundary (So20,w = 7.2 S) was observed during velocity sedimentation of factor VIII at 260,000 x g. A single boundary also was observed for vWF (weight-average So20,w = 21 S) at 42,000 x g. Under condition of excess factor VIII, the weight-average So20,w of the factor VIII-vWF complex was 40 S at 42,000 x g. At 260,000 x g, the factor VIII-vWF complex had sedimented completely, leaving only free factor VIII. The height of the plateau region of the factor VIII sedimentation velocity curve at 260,000 x g was studied as a function of several starting concentrations of vWF. The experiments were done under conditions in which the effect of radial dilution was negligible so that the plateau height was a measure of the concentration of free factor VIII. The plateau height decreased linearly as the concentration of vWF was increased, indicating that the association was essentially irreversible under the conditions used. A stoichiometry of 1.2 vWF monomers/factor VIII molecule was calculated from the slope of the line. Assuming one factor VIII-binding site/vWF monomer, these results indicate that all factor VIII-binding sites are accessible in the vWF multimer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121600

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

2.  FVIII-VWF dos-à-dos.

Authors:  Sriram Krishnaswamy
Journal:  Blood       Date:  2015-08-20       Impact factor: 22.113

3.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Authors:  M W Mosesson; D N Fass; P Lollar; J P DiOrio; C G Parker; G J Knutson; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.

Authors:  D C Hill-Eubanks; C G Parker; P Lollar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

7.  Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.

Authors:  Wenjing Cao; Sriram Krishnaswamy; Rodney M Camire; Peter J Lenting; X Long Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-20       Impact factor: 11.205

8.  The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII.

Authors:  A Leyte; M P Verbeet; T Brodniewicz-Proba; J A Van Mourik; K Mertens
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

9.  A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.

Authors:  Shannon L Meeks; Courtney L Cox; John F Healey; Ernest T Parker; Bhavya S Doshi; Bagirath Gangadharan; Rachel T Barrow; Pete Lollar
Journal:  Blood       Date:  2012-07-31       Impact factor: 22.113

10.  Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.

Authors:  Janneke I Loomans; Eva Stokhuijzen; Marjolein Peters; Karin Fijnvandraat
Journal:  J Clin Transl Res       Date:  2018-02-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.